The gaming landscape continues to see more and more extraction shooters, but none have been quite like this. ARC Raiders is ...

The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no significant overall survival benefit. The study was a double-blind, multicenter ...

Ivonescimab plus chemotherapy improved PFS by 40% compared to Tevimbra in advanced squamous NSCLC, with a median PFS of 11.14 months versus 6.9 months. The study demonstrated consistent PFS benefits ...

Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes ...

– Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with ...

6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings – All clinical responses, including a complete response, ...

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly improved overall survival (OS) among previously treated patients with metastatic ...

Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly ...

BERLIN -- Almost half of patients with advanced ALK-positive non-small cell lung cancer (NSCLC) have lived 7 years or longer following initial treatment with the ALK inhibitor alectinib (Alecensa), an ...